AbbVie (ABBV)
191.50
+2.00 (1.06%)
NYSE · Last Trade: Jun 11th, 9:26 PM EDT
The approval makes Mavyret the first and only oral eight-week direct-acting antiviral therapy for people with Acute Hepatitis C Virus.
Via Stocktwits · June 11, 2025
FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.
Via Benzinga · June 11, 2025
Via Benzinga · June 10, 2025
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Via StockStory · June 9, 2025
Via The Motley Fool · June 8, 2025

Via The Motley Fool · June 5, 2025

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via Benzinga · June 4, 2025

These companies provide growing cash flows.
Via The Motley Fool · June 3, 2025

Via Benzinga · June 2, 2025

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Via Investor's Business Daily · May 29, 2025
AbbVie shares new data for Temab-A, ABBV-706, and PVEK across lung, colorectal, and blood cancers ahead of the ASCO oncology conference.
Via Benzinga · May 27, 2025
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.
Via The Motley Fool · May 24, 2025
Here are three dividend-paying stocks that warrant closer examination.
Via The Motley Fool · May 18, 2025
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.
Via Benzinga · May 16, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 6.7%. This performance was disappointing since the S&P 500 held its ground.
Via StockStory · May 16, 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via Benzinga · May 15, 2025